2007-06-08-世界卫生组织-INN_Proposed_List_103_74页_589kb

Proposed New International Nonproprietary Names (INN)

The World Health Organization has proposed a list (List 103) containing 103 new International Nonproprietary Names (INN) for pharmaceutical substances. These names are proposed by the manufacturer and are subject to public consultation.

New Substances

A variety of therapeutic classes are represented:

• Antineoplastics: crizotinibum (Crizotinib), dacomitinibum (Dacomitinib), betequinibum (Betequinib), danovalinum (Danovalinum), imetelstatum (Imetelstatum), etc.
• Antidiabetics: dulaglutidum (Dulaglutide), fluciclatidum (Fluciclatide), moraglitazolum (Moraglitazolum), roligliptonatum (Rolidoptin), tiprelestatum (Tiprelestatum)
• Cardiovascular: laripirdine (Laripirdine), olrandatenum (Olrandatenum), preclatanenum (Preclatanenum), simiacalcetum (Simiacalcetum), vepipuedenum (Vepipuedenum)
• Analgesics / Neuropsychiatric: alkabemidum (Alkabemidum), diroxamine (Droxamine), kessiglatenum (Kessiglatenum), paracetepipenum (Paracetepipenum), telaparibum (Telaparibum)
• Antivirals: amuvatinibum (Amuvatinibum), anagliptinum (Anagliptinum), etc.
• Others: Beta-blockers (ivabapenenum), diagnostic agents (gadobutrolum, florbetapium (18F)), etc.
• (Note: ABP159 is an abbreviation likely referring to the drug substance itself.)

Key Information

• Submission: Comments must be received within four months of publication.
• Notification: Names proposed by manufacturers receive preferential consideration.
• Procedure: Includes proposal submission, expert review, public consultation, and final selection/rejection based on objections or lack thereof.

Noun Stems for Drug Classification

The proposed names utilize specific noun stems to indicate pharmacological classification (e.g., -antastinum for antihistamines, -cillinum for penicillins, -pyrimidinum for pyrimidines).
(The full list of stems, categorized by therapeutic class, is provided in the original document but too extensive for summary here).

Consultation Period

Comments and objections regarding the proposed names are requested within four months of publication in WHO Drug Information.

Note on Completeness

This summary lists key proposed names from List 103. A complete list of the 103 substances and their full descriptors (including chemical names and actions) can be found in the original publication.